Upgrade to SI Premium - Free Trial

Jefferies sees '+15-30% stock move' for Sarepta Therapeutics (SRPT) following data

March 25, 2026 10:32 AM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles